



FY24 RESULTS PRESENTATION

August 2024

REDOX LIMITED (RDX.ASX)

Presenting today





Raimond Coneliano
Chief Executive Officer &
Managing Director

29 years tenure



Kim Yap
Chief Financial Officer

35 years tenure



Agenda

- 1 FY24 Highlights
- 2 FY24 Financials
- 3 Strategy & Outlook
- 4 Q&A
- 5 Supplementary information



FY24 Highlights

Raimond Coneliano

Chief Executive Officer & Managing Director





\$94.8m

Underlying NPATFX 11.4% growth vs PCP

23.4%

Gross Profit Margin 2.6 ppts above PCP 12.2%

Underlying EBITDAFX Margin 0.8 ppts above PCP

\$115.9m

Cash Flow from operations (Net Cash position \$177m)

11.8%

Proforma Basic Earnings Per Share Growth 19.1%

Underlying after tax Return On Invested Capital

6.5cps

Final Dividend
Total 2024 Dividend 12.2cps

30.8%

Net Working Capital to sales fell by \$18 million

FY24 performance highlights

• Final Dividend declared 6.5cps (12.2cps for FY24). Full year payout ratio of 73% of Statutory Net Profit

NPATFX increased by \$9.7m (up 11.4%) to \$94.8m

• 23.4% Gross Profit Margin achieved due to positive product mix improvements, larger proportion of smaller transactions and diligent margin control

- Positive volume growth achieved in-line with historical average, despite challenging macro-economic environment
- Sales revenue eased by 9.6% due to global price deflation, destocking and weaker customer demand



Key drivers of revenue in FY24





Redox control

Sales team expansion

North American Customer Wins

Portfolio growth

Share of Wallet Initiatives



dox 4%

Growth to 181 reps.
Arizona & Ohio by end CY24

20%

Increase in active customers in North America

+71

Growth in active Product Groups

+30,548

Increase in sales opportunities tracked by **REDEBIZ**

Market factors

Price normalisation post-COVID/Supply Chain Crunch Temporary lull in demand in some segments due to overstocking in FY23

Evolving geopolitical events affecting trade flows & shipping

Ongoing weakness in general economy impacting customer demand



Global Unit Price
Deflation

Destocking

Geo-political uncertainty

Macroeconomic challenges



FY24 performance by segment



FY24 volume growth

- Animal Health & Nutrition supplemental feeding due to dry conditions supported volume gains particularly in 1H FY24
- Crop Production & Protection strengthened as prices stabilised and conditions improved
- Water Care sustained growth from upgraded technical support
- Plastics benefited from the Element Raw Materials acquisition and the onboard of new suppliers and customers
- Mining & Explosives strong growth in sales to the Uranium market
- Industrials buoyant growth in Lubricants and Automotive subsectors
- Human Health & Nutrition enjoyed a boost in Beverages especially in the US

FY24 revenue growth impacted by

- Price deflation prevalent across all key product segments
- Destocking and export controls in Crop Production & Protection
- The closure of key client in the Alumina sector
- Subdued demand in Building (Industrial subsector)


Growth vs FY23	Volume Growth	Revenue Growth
Animal Health & Nutrition	*	-
Crop Production & Protection	*	×
Human Health & Nutrition	✓	×
Household & Personal Care	✓	×
Water Care	*	✓
Plastics, Rubber & Foam	₹	-
Industrial	×	×
Surface Coatings	~	
Mining & Explosives	-	×

FY24 performance by region



Asia Pacific volumes grew strongly in 1H FY24 but the rate of growth slowed in 2H FY24 as customer demand reduced due to the tougher macroeconomic environment

North American volumes grew strongly throughout FY24 with a 36% increase in the number of invoiced sales to customers, revenue grew incrementally despite unit price headwinds





Delivering on our M&A strategy



- Acquisitions add products, customers, suppliers, expertise and capabilities which will drive future growth in line with stated acquisition strategy
- Optigen Ingredients & Element Raw Materials transactions completed in FY24
- Oleum's portfolio now available to larger Redox clientele and sales team
- Redox continue to review several strategic acquisition targets in APAC and North America



Optigen Ingredients

Human Health & Nutrition Australia

(Aug 2023)



Element Raw Materials

Specialty Plastics New Zealand

(Dec 2023)



Oleum

Surfactants & Specialty
Chemical
Australia


(July 2024)

Oleum
completed
July 2024
Integrated within
a few weeks
thanks to Redebiz
CRM/ERP system

Sea Freight Update




- As the vast majority of Redox' product is imported, sea freight and in particular containerised freight rates are a key driver of price for customers
- Containerised freight made up roughly 10% of selling prices during the COVID supply chain crunch
- Due primarily to COVID supply chain constraints, containerised freight prices rose between June 2020, peaked in January 2022 before stabilising in 2023
- In FY24, geopolitical events have resulted in longer ocean transits and capacity constraints leading to higher containerised freight costs
- Higher freight costs will flow into customer prices during FY25
- Redox will continue to provide value to clients during the current supply chain stresses



FY24 Gross Profit



- Strong Gross Profit Margin of 23.4%, beating PCP by 2.6 percentage points
- Margins have been particularly resilient in Australia due to improvements in product portfolio mix, larger proportion of smaller more profitable transactions and diligent margin control
- Due to global price stabilisation and an increase in commodity sales gross margin moderated through the second half of FY24 albeit at levels above historical average





FY24 Financials

Kim Yap
Chief Financial Officer



1.5%

Increase in Gross Profit vs PCP due to disciplined margin management

12.2%

EBITDAFX margin, improvement of 0.8ppts vs PCP

\$95m

Underlying NPATFX improved by 11.4% vs PCP due to higher GP margin and interest income

Profit & Loss overview

	FY24	FY23	Change
	\$m	\$m	%
Revenue	1,137	1,258	-9.6%
Gross profit	266	262	1.5%
Gross margin	23.4%	20.8%	2.6ppts
Underlying EBITDAFX ¹	139	143	-2.9%
Underlying EBITDAFX ¹ margin	12.2%	11.4%	0.8ppts
Underlying NPATFX ¹	95	85	11.4%
Underlying NPATFX ¹ margin	8.3%	6.8%	1.5ppts
Proforma basic Earnings Per Share (cents) ³	17.20	15.38	11.8%
ROIC ²	19.1%	21.6%	-2.5ppts

Notes:


^{1.} Unerlying EBITDAFX and NPATFX excludes unrealised currency revaluations relating to non-cash mark-to-market adjustments on Redox's open forward exchange contracts at period end and the one off listing cost of \$5 million. The mark to market adjustments arise as Redox does not qualify for hedge accounting treatment under the terms of AASB 9 Financial Instruments and so is required to include the non-cash gain or loss on open foreign exchange positions at period end within its statutory result. Redox does not consider these amounts to form part of the Group's "underlying" earnings, and accordingly presents NPATFX metrics which exclude the impacts of these balances.

^{2.} Return on Invested Capital ("ROIC") is defined as net operating profit after tax (NOPAT), divided by average invested capital (total equity plus net debt and lease liabilities).

^{3.} Normalised for the number of shares at the Group's ASX listing on 3 July 2023



Net Profit Before Tax bridge FY23 to FY24





Higher profit margin has more than offset the decline in sales during FY24



Improvement in net working capital and cash position provided a positive contribution to FY24



2.6%

Revenue improvement in North America driven by new customer conversion and strong volume growth

-12.5%

Decrease in Cost Of Goods Sold due primarily to deflation in purchasing prices

2.6ppts

Uplift in Gross Margin vs PCP due to disciplined margin management

Revenue and Gross Profit

	FY24	FY23	Change
	\$m	\$m	%
Revenue – Australia	965	1,063	-9.2%
Revenue – New Zealand	87	107	-18.7%
Revenue – North America	78	76	2.6%
Revenue – Other	8	11	-27.0%
Total revenue*	1,137	1,258	-9.6%
COGS	-871	-995	12.5%
Gross profit	266	262	1.5%
Gross margin	23.4%	20.8%	2.6ppts



\$116M

Cash from operations. \$120m invested in short term deposit

87.6%

Lower free cash flow conversion due to normalisation of Net Working Capital

30.8%

Net working capital as a percentage of revenue higher due to lower working capital requirements

Cash flow

	FY24	FY23	Change
	\$m	\$m	\$m
Cash from operations	116	135	-19
Capex and acquisitions	-5	-3	-2
Net cash flow	111	132	-21
Free cash flow conversion ¹	87.6%	98.5%	
Net working capital (NWC) ²	350	368	18
NWC as % of revenue	30.8%	29.3%	
Net cash/cash equivalent	177	35	142

Notes:

^{1.} Free cash flow conversion is calculated as underlying cash from operations divided by underlying EBITDA (EBITDA minus one off ASX listing costs)

^{2.} Net working capital as a percentage of sales is calculated as period end working capital (the sum of trade and other receivables, inventory, prepayments, other assets, trade and other payables, accruals, provision for income tax and other liabilities) divided by revenue.

Dividend & Dividend Policy



Final Dividend

Final Dividend for FY24 of 6.5 cents per share

Full Year Dividend payout of 12.5cps representing a full year payout ratio of 73% of NPAT within our dividend policy

Final dividend to be paid on the 20th of September 2024

Record date 28th of August 2024

Dividend Policy

Dividend payout ratio is 60%-80% of NPAT



STRATEGY & OUTLOOK

Raimond Coneliano

CEO and Managing Director

Leading distributor of chemicals, ingredients and raw materials



7,000+**ACTIVE CUSTOMERS**



Primary focus organic growth complimented by acquisitions & geographic expansion

Extensive and growing customer, supplier and product base













Largest supplier in Australia by revenue



STRONG TEAM*



PRODUCT GROUPS

Trained the Redox way

^{*} Team includes 180+ salespeople across APAC & USA


Diverse client, industry, product and supplier base




• Largest customer represents ~1.8% of FY24 sales

- Top 10 customers represent ~14.1% of FY24 sales
- Largest individual supplier accounted for ~3.1% of FY24 sales
- Broad geographical supply base that reduces supply risks
- Sourced products from 53 countries in FY24


Sales by Country FY24



Sales by customer concentration FY24



Sales by industry sectors FY24



Outlook

During FY25 Redox will continue to expand our geographic footprint in North America, bolster our product portfolio, increase our share of wallet and grow our client base

We remain focused on driving organic revenue growth and anticipate strong volume growth at or above historical average in FY25

We continue to review strategic M&A opportunities which will contribute to positive momentum

Due to uncertain geopolitical and macroeconomic conditions the company has chosen not to give specific guidance at this time, however the company believes that price deflation and destocking to be largely complete

Gross Profit Margins are expected to ease towards the longer-term average in the medium term as a result of expected expansion in the US and commodity sales volume increase

Redox's strategy and resilient business model has delivered consistent long-term growth and business expansion

The fundamentals of the business are strong and remains well placed to grow into the future



Summary





Leading position in APAC and growing North American presence



Highly cash generative business



Strong operating margins and ROIC



Net working capital has unwound from previous highs



Flexible balance sheet which will be used to fund future growth and a 60-80% dividend payout ratio



Growing importance of chemical distributors within value chain



Continue driving future growth both organically and through strategic acquisitions



Q&A

Raimond Coneliano

CEO and Managing Director

Kim Yap Chief Financial Officer



Supplementary information

Corporate Social Responsibility



Redox aims to be a good corporate citizen embracing positive societal and industry engagement, responsible operation and practical initiatives









Silver Medal for Sustainability received from Ecovadis in 2023

Profit & Loss FY24



	FY24	FY23	Change	FY24 Prospectus	Change
	\$m	\$m	\$m	\$m	\$m
Revenue	1,137.3	1,257.5	-120.2	1,328.2	-190.9
COGS	-871.4	-995.5	124.1	-1,052.8	181.4
Gross profit	265.9	262.0	3.9	275.5	-9.6
Operating expenses excluding depreciation	-127.0	-119.0	-8.0	-127.3	0.3
Underlying EBITDAFX	138.9	143.0	-4.1	148.2	-9.3
Depreciation and amortisation	-8.4	-7.8	-0.6	-7.7	-0.7
Underlying EBITFX	130.5	135.2	-4.7	140.5	-10.0
Net finance costs	4.9	-13.0	17.9	-1.3	6.2
Underlying profit before tax	135.4	122.2	13.2	139.2	-3.8
Effective tax	-40.7	-37.2	-3.5	-41.7	1.0
Underlying NPATFX	94.8	85.0	9.8	97.4	-2.6
Unrealised loss on foreign exchange contracts	-2.0	-4.1	2.1	0	-2.0
Listing cost	-4.5	-2.1	-2.4	-5.2	0.7
Statutory NPAT	90.2	80.7	9.5	94.0	-3.8



Gross Profit increased by \$3.9m vs PCP due to improvement in margin



Underlying profit before tax improved by \$13.2m vs PCP due to outperformance in margin



Increase in admin expenses due to salary inflation and growth in headcount offset by lower bonus payment

Increase in logistics costs due to sales volume growth, rate increases and CPI indexation

Operating costs

	FY24	FY23	Change
	\$m	\$m	\$m
Administration expenses	62	61	-1
Distribution and storage expenses	51	49	-2
Other expenses	22	17	-5
Total underlying operating expenses ¹	135	127	-8
One-off ASX listing costs	5	2	-3
Depreciation and Amortisation	8	8	0
Total operating expenses (excluding D&A)	140	129	-11
Unrealised currency revaluations ² (gain)/loss	2	4	2

Notes:

^{1.} Underlying operating expenses are total operating expenses less one-off ASX listing costs.

^{2.} Unrealised currency revaluations relate to non-cash mark-to-market adjustments on Redox's open forward exchange contracts at period end. These amounts arise as Redox does not qualify for hedge accounting treatment under the terms of AASB 9 Financial Instruments and so is required to include the non-cash gain or loss on open foreign exchange positions at period end within its statutory result. Redox does not consider these amounts to form part of the Group's "underlying" earnings.

Disclaimer



Important notices

This Presentation has been prepared by Redox Limited (ABN 92 000 762 345) ("RDX" or "Company").

Summary information

This Presentation contains summary information about RDX and its activities current as at 30 June 2024. The information in the Presentation is of a general nature and does not purport to be complete or comprise all information which a shareholder or potential investor may require in order to determine whether to deal in RDX shares. It should be read in conjunction with RDX's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at www.asx.com.au.

Not financial product advice

This Presentation is for information purposes only and is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law (and will not be lodged with the Australian Securities and Investments Commission) or under any other law. This Presentation does not constitute financial product, investment, legal, taxation or other advice or a recommendation to acquire RDX shares and has been prepared without considering the objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek financial, legal and taxation advice appropriate to their jurisdiction. The Company is not licensed to provide financial product advice in respect of its shares. Cooling off rights do not apply to the acquisition of RDX shares.

Financial data

All dollar values are in Australian dollars (\$) unless stated otherwise.

Non-IFRS Financial information

RDX's results are reported under International Financial Reporting Standards (IFRS). This presentation also includes certain non-IFRS measures including "underlying", "adjusted" and "pro-forma" and other measures that are used internally by management to assess the operational performance and management of the Group. Non-IFRS measures have not been subject to audit or review. All numbers listed as "statutory" comply with IFRS and have been audited.

Past performance

Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as an indication of future performance.

Future performance

This presentation contains certain "forward-looking statements" including statements regarding our intent, belief or current expectations with respect to the Company's business and operations, market conditions, results of operations and financial condition, and risk management practices. The words "likely", "expect", "aim", "should", "could", "may", "anticipate", "predict", "believe", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. This Presentation contains such statements that are subject to risk factors associated with an investment in RDX. RDX believes that the expectations reflected in these statements are reasonable, but they may be affected by a range of variables which could cause actual results or trends to differ materially.

REDÓX







RedoxTweet



Redox Limited



Redox_global